|
Market Closed -
Sao Paulo
10:16:17 2026-10-19 am EDT
|
5-day change | 1st Jan Change | ||
| 79.36 BRL | -0.30% |
|
-0.90% | +1.43% |
| Oct. 15 | Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $654 From $653 | MT |
| Oct. 09 | Vertex Pharmaceuticals Says Alyftrek Delivers Pancreatic Function Recovery in Some Children | MT |
| Market Cap | 130B 655B 116B 108B 97.54B 183B 12,362B 186B 1,292B 507B 6,465B 489B 479B 20,644B | P/E 2026 * |
34.3x | P/E 2027 * | 27.6x |
|---|---|---|---|---|---|
| Enterprise Value | 125B 627B 111B 103B 93.26B 175B 11,819B 178B 1,235B 485B 6,181B 468B 458B 19,737B | EV / Sales 2026 * |
9.4x | EV / Sales 2027 * | 8.44x |
| Free-Float |
99.79% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Vertex Pharmaceuticals Incorporated
| 1 day | -0.30% | ||
| 1 week | -0.90% | ||
| Current month | -7.57% | ||
| 1 month | -7.05% | ||
| 3 months | +2.32% | ||
| 6 months | +15.20% | ||
| Current year | +1.43% |
| 1 week | 79 |  | 79.6 |
| 1 month | 76.36 | | 86.22 |
| Current year | 65.18 | | 89.01 |
| 1 year | 65.18 | | 89.01 |
| 3 years | 52.29 | | 93.56 |
| 5 years | 31.33 | | 93.56 |
| 10 years | 20.29 | | 93.56 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 2020-03-31 | |
Charles Wagner
DFI | Director of Finance/CFO | 57 | 2019-04-09 |
Sean Daughtry
CTO | Chief Tech/Sci/R&D Officer | - | 2024-02-29 |
| Director | Title | Age | Since |
|---|---|---|---|
Bruce Sachs
BRD | Director/Board Member | 66 | 1997-12-31 |
Jeffrey Leiden
CHM | Chairman | 70 | 2012-04-30 |
Sangeeta Bhatia
BRD | Director/Board Member | 57 | 2015-06-17 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.30% | -0.90% | - | - | 127B | |
| +3.49% | +8.54% | +59.89% | +117.27% | 1,106B | |
| +2.19% | -1.66% | +34.23% | +70.27% | 612B | |
| +2.26% | +2.83% | +25.92% | +98.65% | 500B | |
| +2.58% | +8.31% | +37.43% | +63.51% | 367B | |
| +3.25% | +1.96% | +74.90% | +47.67% | 354B | |
| +1.85% | +5.45% | +21.38% | +49.26% | 286B | |
| +1.76% | +4.92% | +0.48% | +20.31% | 256B | |
| +3.29% | +5.12% | +46.90% | +56.43% | 230B | |
| +2.25% | +4.04% | +27.44% | +99.53% | 190B | |
| Average | +0.70% | +2.13% | +36.51% | +69.21% | 433.35B | |
| Weighted average by Cap. | +0.42% | +2.30% | +41.69% | +80.33% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 13.27B 66.66B 11.82B 10.95B 9.92B 18.66B 1,257B 18.93B 131B 51.58B 658B 49.77B 48.73B 2,100B | 14.56B 73.17B 12.97B 12.02B 10.89B 20.49B 1,380B 20.78B 144B 56.62B 722B 54.63B 53.49B 2,305B |
| Net income | 3.89B 19.55B 3.47B 3.21B 2.91B 5.47B 369B 5.55B 38.54B 15.13B 193B 14.59B 14.29B 616B | 4.89B 24.58B 4.36B 4.04B 3.66B 6.88B 464B 6.98B 48.47B 19.02B 242B 18.35B 17.97B 774B |
| Net Debt | -5.73B -28.8B -5.11B -4.73B -4.29B -8.06B -543B -8.18B -56.79B -22.29B -284B -21.5B -21.05B -907B | -7.54B -37.9B -6.72B -6.23B -5.64B -10.61B -715B -10.76B -74.73B -29.33B -374B -28.29B -27.7B -1,194B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-19 | R$79.36 | -0.30% | 1,888 |
| 26-10-16 | R$79.60 | +0.71% | 1 |
| 26-10-14 | R$79.04 | +3.35% | 2 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- VRTX Stock
- VRTX34 Stock
Select your edition
All financial news and data tailored to specific country editions
